NCT06649383 Virtual Reality (VR) Could Be a Good Alternative to Relaxing or Pain-relieving Medication
| NCT ID | NCT06649383 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Pether Jildenstal |
| Condition | Virtual Reality |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2027-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 90 participants in total. It began in 2024-12-16 with a primary completion date of 2027-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We want to investigate whether Virtual Reality (VR) could be a good alternative to the relaxing or pain-relieving medications that are often used to alleviate anxiety when patients undergo surgery under local anesthesia.
Eligibility Criteria
Inclusion Criteria: * over 65 years, planed surgery in local anesthesia/regional anesthesia Exclusion Criteria: * dementia, unable to cooperate, cognitive impairment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06649383 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Virtual Reality. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06649383 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06649383 currently recruiting?
Yes, NCT06649383 is actively recruiting participants. Contact the research team at pether.jildenstal@vgregion.se for enrollment information.
Where is the NCT06649383 trial being conducted?
This trial is being conducted at Alingsås, Sweden, Gothenburg, Sweden.
Who is sponsoring the NCT06649383 clinical trial?
NCT06649383 is sponsored by Pether Jildenstal. The trial plans to enroll 90 participants.